Practical Guidance on the Use of Vaginal Laser Therapy: Focus on Genitourinary Syndrome and Other Symptoms
Victoria Kershaw,Swati Jha
DOI: https://doi.org/10.2147/ijwh.s446903
2024-11-16
International Journal of Women s Health
Abstract:Victoria Kershaw, 1 Swati Jha 2 1 James Cook University Hospital, Middlesbrough, TS4 3BW, UK; 2 Jessop Wing, Tree Root Walk, Sheffield, S10 2SF, UK Correspondence: Victoria Kershaw, Gynaecology Department, James Cook University Hospital, Marton Road, Middlesbrough, TS4 3BW, UK, Tel +01609 763075, Email Genitourinary syndrome of the menopause (GSM) is a chronic, often progressive condition, characterised by symptoms relating to oestrogen deficiency including; vaginal dryness, burning, itching, dyspareunia, dysuria, urinary urgency and recurrent urinary tract infections. GSM affects up to 70% of breast cancer survivors with a tendency to particularly severe symptoms, owing to the effects of iatrogenic menopause and endocrine therapy. Patients and clinicians can be reluctant to replace oestrogen vaginally due to fear of cancer recurrence. Vaginal laser is a novel therapy, which may become a valuable nonhormonal alternative in GSM treatment. There are currently 6 published studies regarding Erbium:YAG laser treatment for GSM, 41 studies regarding CO2 laser treatment for GSM and 28 studies regarding vaginal laser treatment for GSM in breast cancer survivors. Number of participants ranges from 12 to 645. The majority of studies describe a course of 3 treatments, but some report outcomes after 5. Significant improvements were reported in vaginal dryness, burning, dyspareunia, itch, Vaginal Health Index Scores (VHIS), Quality of Life, and FSFI (Female Sexual Function Index). Most studies reported outcomes at short-term follow-up from 30 days to 12 months post-treatment. Few studies report longer-term outcomes with conflicting results. Whilst some studies suggest improvements are sustained up to 24 months, others report a drop-off in symptom improvement at 12– 18 months. Patient satisfaction ranged from 52% to 90% and deteriorated with increasing time post-procedure in one study. The findings in this review must be validated in robust randomised sham-controlled trials of adequate power. There remain a number of unanswered questions in terms of which laser medium to use, optimal device settings, ideal interval between treatments, pre-treatment vaginal preparation, as well as safety and efficacy of repeated treatments long term. These issues could be addressed most efficiently with a mandatory registry of vaginal laser procedures. Keywords: vaginal laser, breast cancer, genitourinary syndrome of the menopause, GSM, CO2, Erbium:YAG, vulvovaginal atrophy Genitourinary syndrome of menopause (GSM) is the term used to describe symptoms of oestrogen deficiency related to changes in the vulva, vagina and lower urinary tract. 1,2 Prior to the introduction of this consensus terminology in 2014, these changes were commonly referred to as vulvovaginal atrophy. 2 GSM is characterised by a number of clinical symptoms including: genital symptoms of dryness (up to 100%), burning (57%), itching (57%), and irritation (77%); sexual symptoms of lack of lubrication and dyspareunia (78%); and urinary symptoms of dysuria (6%), urgency and recurrent urinary tract infections. 2–4 Although women may present with one or multiple symptoms, the most common symptom of GSM is vaginal dryness. 5–8 A high concentration of oestrogen receptors exist in the vagina, vestibule, and trigone of the bladder. The decline of circulating oestrogen leads to a reduced collagen content, decreased elastin, thinning of the epithelium, altered function of smooth muscle cells and fewer blood vessels. This results in anatomical changes including regression and thinning of the labia minora, retraction of the introitus with reduced elasticity (often leading to entry dyspareunia), prominence of the urethral meatus (making it vulnerable to physical irritation and trauma), reduction in vaginal blood flow and diminished lubrication. Increased friability may predispose to epithelial damage with vaginal penetration, leading to vaginal pain, fissuring and bleeding after sex. 2 In the pre-menopausal state, the stratified squamous vaginal epithelium is thick with rugae. 9 As epithelial cells exfoliate and die, they release glycogen, which is subsequently transformed to lactic acid by the action of a normal vaginal commensal organism, lactobacillus. At menopause, the epithelium becomes thinner, leading to a reduction in the shedding of glycogenated cells and subsequent loss of lactobacilli, resulting in an increased pH and change to the microbiome. 2 This leads to an increased growth of pathogenic bacteria such as streptococci, staphylococci, and coliforms, which in turn, can cause vaginal inflammation and urogenital infections. 10 GSM is a chronic and often progressive condition, impacting the quality of life of up to 50% of postmenopausal women. 2 -Abstract Truncated-
obstetrics & gynecology